Please login to the form below

Not currently logged in
Email:
Password:

Hanmi Pharmaceutical

This page shows the latest Hanmi Pharmaceutical news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment. Merck/MSD has reached a licensing agreement with Korea’s Hanmi Pharmaceutical for an investigational GLP-1/glucagon dual receptor agonist for nonalcoholic steatohepatitis (NASH). ... The deal with

Latest news

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly licensed HM71224 (LY3337641) from South Korean biotech Hanmi Pharmaceutical in 2015 for $50m upfront and milestones of $640m, but after two years of phase II testing has concluded that there ... Hanmi reported the decision to the Korean financial

  • Lilly inks $690m deal with Hanmi for autoimmune drug Lilly inks $690m deal with Hanmi for autoimmune drug

    Hanmi Pharmaceutical. ... HM71224 has shown promising activity in preclinical studies and a phase I study in Europe, according to Gwan Sun Lee, Hanmi's chief executive.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch November 2015 Deal Watch November 2015

    $900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.

  • Country report: The healthcare market in South Korea Country report: The healthcare market in South Korea

    Dong-A, Yoohan, Hanmi, Green Cross and Choongwhe Pharmaceuticals have led in terms of sales. ... Korea's key players ($m). Ranking. Company. Sales. R&D. 1. Donga Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics